Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria
Phillip Scheinberg(National Heart Lung and Blood Institute), Austin Kulasekararaj(King's College London), Sasha Sreckovic, Marek Hus(Medical University of Lublin), Simon Buatois(Roche (Switzerland)), Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Anna Kiialainen(Roche (Switzerland)), Erfan Nur(Sanquin), Himika Patel, Valentina Giai(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Brittany Gentile, Cristina Barrenetxea Lekue(Hospital de Basurto), Mustafa Nuri Yenerel(Istanbul University), Marianne Uguen(Roche (Switzerland)), Yoojin Lee(Ulsan College), Jin Seok Kim(National Health Insurance Service Ilsan Hospital), Yasutaka Ueda(The University of Osaka), John Edwards(Indiana Cancer Consortium), Zsolt Nagy(Semmelweis University), Jens Panse(University Hospital Cologne), Debora Bonito, Diego V. Clé(Universidade de Ribeirão Preto)
Cited by 42
Related Papers
Immune dysregulation in human subjects with heterozygous germline mutations in <i>CTLA4</i>
|Science|2014|844
Guidelines for the diagnosis and management of adult aplastic anaemia
|British Journal of Haematology|2015|750
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
Danazol Treatment for Telomere Diseases
|New England Journal of Medicine|2016|401